Moreover, the infrequency of grade 4 myelotoxicity makes this regimen particularly attractive for the treatment of patients who are not able to tolerate more toxic chemotherapy-based regimens.
Overall severe non-haematologic toxicity (28.4% vs 36.8% P=0.001) occurred less frequently in the CD arm, making this regimen an attractive option with a favourable therapeutic index for patients with platinum-sensitive ROC.
The thrombocytopenia was manageable with PBSC support, but makes this regimen unlikely to be applied outside the research setting because of the risk of bleeding, particularly if combined with other predisposing factors.
Anyway, the short-lasting infusion of all cytotoxic drugs over a few hours in two separate days made this regimen convenient also for an out-patient management, because the placement of an indwelling central venous catheter and/or the use of infusional devices were not required.
Thus, apart from the favorable properties already attributed to recombinant MVA [33], the possibilities of dose sparing and single shot immunization regimens make this vector even more attractive as a pandemic influenza vaccine candidate.
Despite the sustained success of ART against HIV-1 infection and the significant improvements made to this regimen, as long as it must be taken daily for a lifetime, there will be a desire to cure HIV-1 infection using a single treatment.
In addition, we replaced the cisplatin with carboplatin to make the regimen more convenient for patients.
Indeed, these can work synergistically with insulin to make the regimen more effective (Wright et al 2002).
However, the 72 h infusion makes this an inconvenient regimen.
After maximal swelling had occurred, rats received an oral daily dose of WAY-169916, making this a therapeutic dosing regimen.
